Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
暂无分享,去创建一个
Qingliang Meng | Huan Huang | Jihong Liu | Qinglian Meng | Guozhong Niu | Huan Huang | Guozhong Niu | Jihong Liu
[1] Changxing Shen,et al. Overexpression of adenylate cyclase-associated protein 1 may predict brain metastasis in non-small cell lung cancer. , 2015, Oncology reports.
[2] Yuemao Shen,et al. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. , 2012, Drug discoveries & therapeutics.
[3] G. Pasternak,et al. The role of multidrug resistance‐associated protein in the blood–brain barrier and opioid analgesia , 2013, Synapse.
[4] G. Melloni,et al. Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience. , 2011, The Journal of cardiovascular surgery.
[5] W. Berger,et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications , 2005, Journal of Cancer Research and Clinical Oncology.
[6] F. Yang,et al. The impact of Caspase-8 on non-small cell lung cancer brain metastasis in II/III stage patient. , 2015, Neoplasma.
[7] F. Gao,et al. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines. , 2011, Oncology reports.
[8] Zj Chen,et al. Lung Resistance Protein and Multidrug Resistance Protein in Non-Small Cell Lung Cancer and Their Clinical Significance , 2011, The Journal of international medical research.
[9] D. Miller,et al. Surgical treatment of primary lung cancer with synchronous brain metastases. , 2001, The Journal of thoracic and cardiovascular surgery.
[10] G. Giaccone,et al. Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer , 2001 .
[11] M. Sonobe,et al. Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer , 2014, International Journal of Clinical Oncology.
[12] Liancong Wang,et al. Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients. , 2013, Molecular and clinical oncology.
[13] U. Abacıoğlu,et al. Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients? , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[14] Chen Li,et al. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer , 2010, BMC Cancer.
[15] Jun Liang,et al. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. , 2014, International journal of radiation oncology, biology, physics.
[16] A. Twijnstra,et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.
[17] Moon Soo Kim,et al. A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. , 2015, Lung cancer.